cytochrome P450 family 2 subfamily J member 2Genealiases: CPJ2 · CYPIIJ2
Q-omics provides the consensus-scored CYP2J2 profile across patient tissues and cancer cell-line models. CYP2J2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CYP2J2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CYP2J2 RNA expression shows 16,265 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where CYP2J2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2J2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2J2 survival associations across molecular data types. CYP2J2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2J2 RNA expression–survival associations across cancer types. High CYP2J2 expression shows unfavorable associations in KIRP, THYM, KICH, ACC and ESCA, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CYP2J2 RNA expression.
This table summarizes CYP2J2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CYP2J2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2J2 shows lower tumor expression in HNSC, KICH, COAD and READ and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher CYP2J2 RNA expression in tumor versus normal tissue (log2 FC = +5.320, t-test p < 0.001).
This table shows molecular features associated with CYP2J2 in patient tissues and cancer cell lines. In patient samples, CYP2J2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP2J2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
